IRCT20150721023282N11 IRCT 2020-07-13 Esfahan University of Medical Sciences Evaluation of the effect of the combination of coenzyme Q10, alpha-lipoic acid, and acetyl-L-carnitine in the prevention of anti-tuberculosis drugs-induced hepatic adverse effect Evaluation of the effect of the combination of coenzyme Q10, alpha-lipoic acid, and acetyl-L-carnitine compared to placebo in the prevention of anti-tuberculosis drugs-induced hepatotoxicity 2017-04-04 anticipated 90 Complete https://irct.ir/trial/49526 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Prevention, Randomization description: Simple randomization was used for patients' allocation to the groups. For this, an online random number generator was used (available at: https://www.random.org/sequences) so that even and odd numbers were considered for experimental and placebo groups, respectively, and each patient, after inclusion, was assigned to the related group according to the determined sequence, Blinding description: Drug and placebo capsules will be fully similar and packaged in similar containers. The patient, the prescriber (physician), data analyst, and the laboratory personnel will be blind to the content of containers and intervention type. 2-3 Anti-tuberculosis drugs-induced hepatotoxicity. Intervention 1: Intervention group: oral capsules containing the combination of CoQ10 (200 mg) + alpha-lipoic acid (250 mg) + acetyl-L-carnitine (250 mg) manufactured by Vitacost cmpany, USA, twice daily, for 2 weeks, with standard 4-drug anti-TB therapeutic regimen including isoniazid 5 mg/kg + rifampin 10 mg/kg + ethambutol 15 mg/kg + pyrazinamide 25 mg/kg. Intervention 2: Control group: placebo capsules, manufactured by Isfahan faculty of Pharmacy, twice daily, for 2 weeks, with standard 4-drug anti-TB therapeutic regimen including isoniazid 5 mg/kg + rifampin 10 mg/kg + ethambutol 15 mg/kg + pyrazinamide 25 mg/kg. No - There is not a plan to make this available Justification or reason for not sharing IPD is Confidentiality of patients' data